PMA device
Paradigm Real-Time Insulin Pump
Medtronic Minimed · Sensor, Glucose, Invasive (MDS, Class III) · First FDA decision Dec 16, 2008, newest Aug 25, 2015Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
12
Naming "Paradigm Real-Time Insulin"
MAUDE reports
133,322
Brand "Paradigm Real-Time Insulin", since 2015
PubMed studies
0
Mentioning "Paradigm Real-Time Insulin"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Paradigm Real-Time Insulin Pump
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
P980022-S176 · Decided Aug 25, 2015 · 189 days after receipt · Normal 180 Day Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
P980022-S133 · Decided Jan 15, 2014 · 327 days after receipt · Normal 180 Day Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
P980022-S037 · Decided Dec 16, 2008 · 56 days after receipt · Normal 180 Day Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Paradigm Real-Time Insulin", any status and sponsor, newest update first.
- Study of Insulin Therapy Augmented by Real Time Sensor IN Type 1 Children and Adolescents (START-IN!)Pivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00949221 · 150 participants · Start Sep 2009 · Primary completion Jul 2012
Device: monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE · For: Type 1 Diabetes
Sites: Paris, France
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
NCT01030341 · 45 participants · Start May 2011 · Primary completion Nov 2014
Device: CGMS and insulin pump · For: Diabetic Gastroparesis
Sites: San Francisco, California; Stanford, California; Ann Arbor, Michigan · 7 sites in all
- SWITCH - Sensing With Insulin Pump Therapy to Control HbA1cPivotal-lookingCompleted
Medtronic MiniMed, Inc.Public (MDT)
NCT00598663 · 153 participants · Start Jan 2008 · Primary completion Jul 2010
Device: insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System); insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump) · For: Diabetes Mellitus, Type 1
Sites: Vienna, Austria; Copenhagen, Denmark; Glostrup Municipality, Denmark · 8 sites in all
9 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Paradigm Real-Time Insulin", and for the whole product code for context.
This brand
133,322 reports: 125,010 malfunction, 8,140 injury, 154 death
Whole product code MDS
232,139 reports: 226,671 malfunction, 5,201 injury, 215 death
Newest reports for this brand
Medtronic Puerto Rico Operations Co.
2032227-2026-264782 · Received Oct 30, 2026 · Event dated Oct 9, 2026
Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Device problem as coded: Mechanical Problem; Obstruction of Flow
Patient problem as coded: Hyperglycemia; Malaise
Medtronic Puerto Rico Operations Co.
2032227-2026-263573 · Received Oct 29, 2026 · Event dated Oct 22, 2026
Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Device problem as coded: Display or Visual Feedback Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Medtronic Puerto Rico Operations Co.
2032227-2026-263628 · Received Oct 29, 2026 · Event dated Oct 22, 2026
Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Device problem as coded: Display or Visual Feedback Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Paradigm REAL-Time Insulin Pump (MMT-522, MMT-722)Open, Classified
Z-1749-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026
Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...
Cause as FDA categorized it: Device Design · Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
- Paradigm REAL-Time Revel Insulin Pump (MMT-523, MMT-723)Open, Classified
Z-1750-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026
Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...
Cause as FDA categorized it: Device Design · Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Z-1256-2025 · Started Jan 31, 2025 · Posted by FDA Mar 3, 2025
Reason given: All Medtronic MiniMed pumps (Paradigm series, Minimed 530G, 6XX series, and 7XX series) were found to have the potential for abnormal insulin delivery due to changes in air pressure, which can be found during airplane take-off or landing. An unexpected additional dose of insulin, which can occur during take-off, can...
Cause as FDA categorized it: Device Design · Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
11 more recall records with a free account
Published research
The most relevant PubMed records for "Paradigm Real-Time Insulin"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MDS.
- Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2018
- G5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2024
- FreeStyle Libre Pro Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2020
- Freestyle Navigator Continuous Glucose Monitoring SystemAbbott Laboratories · PMA 2011
- Medtronic Minimed Continuous Glucose Monitoring SystemMedtronic Minimed · PMA 2011
- Guardian Connect SystemMedtronic Minimed · PMA 2025
- Dexcom Seven SystemDexcom, Inc. · PMA 2009
- Guardian RtMedtronic Minimed · PMA 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.